RxDoctor Payments DataLook up a doctor →

Laszlo Mechtler, MD

Neurology · Amherst, NYNPI 1710978598

Payments from drug & device makers

$4,256,087in general payments, 2019–2025

Across 1,769 payments — averaging $2405.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.5M
  • AbbVie$1.3M
  • Amgen$398K
  • Neurology Practice Consortium GPO, LLC$307K
  • H. Lundbeck A S$261K
  • Teva Pharmaceuticals USA, Inc.$164K
  • plus $316K from 54 others
$18,674in research payments, 2019–2025

Across 13 payments — averaging $1436.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$9K
  • Pfizer$9K

What the payments were for

  • Consulting fees$102,38529%
  • Speaking & faculty fees$206,45459%
  • Travel & lodging$7,9752%
  • Food & beverage$30,2729%
  • Education$1910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly28$1,477,113
AbbVie(2 entities)469$1,332,164
Amgen142$398,338
Neurology Practice Consortium GPO, LLC7$307,407
H. Lundbeck A S48$260,755
Teva Pharmaceuticals USA, Inc.211$164,017
Hyperfine Operations, Inc.4$143,877
Lundbeck LLC77$41,001
Merz Pharmaceuticals, LLC4$25,000
Biohaven Pharmaceutical Holding Company Ltd.58$22,225
Impel Pharmaceuticals Inc.53$21,983
Biohaven Pharmaceuticals, Inc.85$21,384
Pfizer63$12,379
Novartis44$10,216
Currax Pharmaceuticals LLC106$5,941
Promius Pharma LLC7$3,522
Tonix Medicines, Inc.92$3,080
Lilly USA, LLC55$1,228
UCB, Inc.23$488
Upsher-smith Laboratories LLC28$440
Impel Pharmaceuticals LLC12$242
Scilex Pharmaceuticals Inc.15$226
Averitas Pharma Inc.4$215
Supernus Pharmaceuticals, Inc.14$214
Axsome Therapeutics, Inc.11$213
Eisai Inc.7$162
Acadia Pharmaceuticals Inc3$157
Abbott1$155
SK Life Science, Inc.7$142
Arbor Pharmaceuticals, Inc.3$133
Avanir Pharmaceuticals, Inc.7$124
Novocure Inc.9$121
Novo Nordisk5$110
Boston Scientific2$108
Springworks Therapeutics, Inc.5$99
Ipsen Biopharmaceuticals, Inc3$93
Otsuka America Pharmaceutical, Inc.4$93
Assertio Therapeutics, Inc.7$92
IBSA Pharma Inc.5$84
Azurity Pharmaceuticals, Inc.4$82
Merck4$71
Jazz Pharmaceuticals Inc.3$57
Neurocrine Biosciences, Inc.2$49
Zyla Life Sciences, Inc.3$43
Alkermes, Inc.2$42
Tersera Therapeutics LLC2$38
Johnson & Johnson(2 entities)2$36
Greenwich Biosciences, Inc.2$36
Idorsia Pharmaceuticals US Inc2$34
Octapharma USA, Inc.1$25
Sunovion Pharmaceuticals Inc.1$23
Biogen1$22
Genentech USA, Inc.1$21
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$21
Adamas Pharmaceuticals, Inc.1$20
AstraZeneca1$19
GE HealthCare2$17
Bausch Health US, LLC1$16
Daiichi Sankyo Inc.1$15
Shire North American Group Inc1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,256,087 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$582,751
Medicare patients
866
Services billed
20,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate46$61,346
BotoxOnabotulinumtoxina18$23,701
QuliptaAtogepant18$19,728
Aimovig AutoinjectorErenumab-Aooe12$8,782
Sumatriptan Succinate26$3,021
Divalproex Sodium ErDivalproex Sodium30$1,610
Aspirin-Dipyridamole ErAspirin/Dipyridamole11$1,519
Oxcarbazepine20$1,433
Levetiracetam67$1,411
Amitriptyline Hcl95$1,116
Dexamethasone23$854
Lacosamide11$752
Nortriptyline Hcl38$357
Topiramate21$301
Donepezil Hcl14$294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$12,379$61,34646 claims
AbbVieBotox, Qulipta$1,332,164$43,42836 claims
Upsher-smith Laboratories LLCTopiramate$440$30121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →